Presentations from the May 21-23 HIV Vaccine Trials Network (HVTN) Meeting

HIV Treat Bull - 2008 July-August;9(7/8):

The HVTN has made available the Powerpoint files of presentations from their recent meeting in DC. [1]

Of particular interest, Surojit Sarkar from Emory presents data indicating that - as suggested by the longitudinal data from trials of Merck’s HIV vaccine - CD8 T cell responses induced by Ad5 vectors do no contract in the way that typically occurs during the development of protective memory T cell responses, and that this is associated with the persistence of the vector. [2]

As a result, Ad5-induced CD8 T cell responses appear functionally compromised and display poor proliferative capacity and protective efficacy in Sarkar’s murine studies.

David Watkins also contrasts the breadth of T cell responses that he observes in macaque vaccine studies (6-18 CD8 T cell epitopes) with those observed in the Merck vaccine efficacy trial (3 CD8 T cell epitopes), and several other presenters discuss strategies for improving the number of epitopes targeted by HIV-specific T cell responses. Based on a prior comment to this blog by Ian York, it is to be hoped that members of relevant NIH study sections are being educated about the potential importance of improving the breadth of vaccine-induced T cell responses in humans. [3, 4]

Source: TAG Basic Science Blog (4 Jun 2008) http://tagbasicscienceproject.typepad.com/tags_basic_science_vaccin/2008/05/treatment-actio.html

References
1. http://www.hvtn.org/meeting/may08.html
2. http://tagbasicscienceproject.typepad.com/tags_basic_science_vaccin/2008/04/after-the-fact.html
3. http://tagbasicscienceproject.typepad.com/tags_basic_science_vaccin/2008/04/hints-of-correl.html#comment-110221934
4. http://www.iayork.com/MysteryRays

2008-07-10
IB080907-22

©2008. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.